Cox univariate analysis outcomes by toxicity type for irAE CTCAE grades 1–2 or grade 1–4 versus grade 0
| Toxicity type | HR (95% CI) | |
| RFS | OS | |
| Any irAE grades 1–2 | 0.60 (0.52 to 0.90), p=0.006 | 0.71 (0.49 to 1.02), p=0.065 |
| Any irAE grades 1–4 | 0.71 (0.55 to 0.93), p=0.011 | 0.82 (0.58 to 1.17), p=0.270 |
| Rash grades 1–2 | 0.75 (0.62 to 0.90), p=0.002 | 0.70 (0.55 to 0.89), p=0.004 |
| Rash grades 1–4 | 0.77 (0.65 to 0.92), p=0.004 | 0.74 (0.59 to 0.94), p=0.012 |
| Endo grades 1–2 | 0.75 (0.61 to 0.92), p=0.005 | 0.76 (0.58 to 0.99), p=0.045 |
| Endo grades 1–4 | 0.79 (0.65 to 0.97), p=0.015 | 0.84 (0.65 to 1.08), p=0.168 |
| Endo and rash grades 1–2 | 0.65 (0.53 to 0.78), p<0.001 | 0.63 (0.48 to 0.81), p<0.001 |
| Endo and rash grades 1–4 | 0.73 (0.57 to 0.92), p=0.009 | 0.73 (0.57 to 0.92), p<0.001 |
| GI grades 1–2 | 0.87 (.72 to 1.05), p=0.137 | 0.88 (0.69 to 1.13), p=0.305 |
| GI grades 1–4 | 0.88 (0.74 to 1.06), p=0.171 | 0.94 (0.74 to 1.18), p=0.590 |
irAE, immune-related adverse event; OS, overall survival; RFS, relapse-free survival.